1 |
Xu Z, Liu G, Zhang M, Zhang Z, Jia Y, Peng L, et al. miR-122-5p inhibits the proliferation, invasion and growth of bile duct carcinoma cells by targeting ALDOA. Cell Physiol Biochem 2018;48:2596-2606.
DOI
|
2 |
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
DOI
|
3 |
Gatta G, Rossi S, Capocaccia R. Cancer burden estimates and forecasts: uses and cautions. Tumori 2013;99:439-443.
DOI
|
4 |
Fu DG. Epigenetic alterations in gastric cancer (review). Mol Med Rep 2015;12:3223-3230.
DOI
|
5 |
Khatami F, Karbakhsh M. Socioeconomic position and incidence of gastric cancer: a systematic review and meta-analysis. J Epidemiol Community Health 2015;69:818-819.
DOI
|
6 |
Yoon H, Kim N. Diagnosis and management of high risk group for gastric cancer. Gut Liver 2015;9:5-17.
DOI
|
7 |
Stojanovic J, Tognetto A, Tiziano DF, Leoncini E, Posteraro B, Pastorino R, et al. MicroRNAs expression profiles as diagnostic biomarkers of gastric cancer: a systematic literature review. Biomarkers 2019;24:110-119.
DOI
|
8 |
Yuan HL, Wang T, Zhang KH. MicroRNAs as potential biomarkers for diagnosis, therapy and prognosis of gastric cancer. Onco Targets Ther 2018;11:3891-3900.
DOI
|
9 |
Wu Q, Ren X, Zhang Y, Fu X, Li Y, Peng Y, et al. MiR-221-3p targets ARF4 and inhibits the proliferation and migration of epithelial ovarian cancer cells. Biochem Biophys Res Commun 2018;497:1162-1170.
DOI
|
10 |
Deng L, Lei Q, Wang Y, Wang Z, Xie G, Zhong X, et al. Downregulation of miR-221-3p and upregulation of its target gene PARP1 are prognostic biomarkers for triple negative breast cancer patients and associated with poor prognosis. Oncotarget 2017;8:108712-108725.
DOI
|
11 |
Duan Y, Dong Y, Dang R, Hu Z, Yang Y, Hu Y, et al. MiR-122 inhibits epithelial mesenchymal transition by regulating P4HA1 in ovarian cancer cells. Cell Biol Int 2018;42:1564-1574.
DOI
|
12 |
Tao K, Yang J, Guo Z, Hu Y, Sheng H, Gao H, et al. Prognostic value of miR-221-3p, miR-342-3p and miR- 491-5p expression in colon cancer. Am J Transl Res 2014;6:391-401.
|
13 |
Xu X, Gao F, Wang J, Tao L, Ye J, Ding L, et al. MiR-122-5p inhibits cell migration and invasion in gastric cancer by down-regulating DUSP4. Cancer Biol Ther 2018;19:427-435.
DOI
|
14 |
Barajas JM, Reyes R, Guerrero MJ, Jacob ST, Motiwala T, Ghoshal K. The role of miR-122 in the dysregulation of glucose-6-phosphate dehydrogenase (G6PD) expression in hepatocellular cancer. Sci Rep 2018;8:9105.
DOI
|
15 |
Ergun S, Ulasli M, Igci YZ, Igci M, Kirkbes S, Borazan E, et al. The association of the expression of miR- 122-5p and its target ADAM10 with human breast cancer. Mol Biol Rep 2015;42:497-505.
DOI
|
16 |
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105:10513-10518.
DOI
|
17 |
Heinemann FG, Tolkach Y, Deng M, Schmidt D, Perner S, Kristiansen G, et al. Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma. Clin Epigenetics 2018;10:11.
DOI
|
18 |
Uen Y, Wang JW, Wang C, Jhang Y, Chung JY, Tseng T, et al. Mining of potential microRNAs with clinical correlation - regulation of syndecan-1 expression by miR-122-5p altered mobility of breast cancer cells and possible correlation with liver injury. Oncotarget 2018;9:28165-28175.
DOI
|
19 |
Pei ZJ, Zhang ZG, Hu AX, Yang F, Gai Y. miR-122-5p inhibits tumor cell proliferation and induces apoptosis by targeting MYC in gastric cancer cells. Pharmazie 2017;72:344-347.
|
20 |
Li M, Zhou Y, Xia T, Zhou X, Huang Z, Zhang H, et al. Circulating microRNAs from the miR-106a-363 cluster on chromosome X as novel diagnostic biomarkers for breast cancer. Breast Cancer Res Treat 2018;170:257-270.
DOI
|
21 |
Wang X, Jia Z, Shi H, Pan C. Identification and evaluation of 2 circulating microRNAs for non-small cell lung cancer diagnosis. Clin Exp Pharmacol Physiol 2018;45:1083-1086.
DOI
|
22 |
Ho AS, Huang X, Cao H, Christman-Skieller C, Bennewith K, Le QT, et al. Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol 2010;3:109-113.
DOI
|
23 |
Zhou CF, Ma J, Huang L, Yi HY, Zhang YM, Wu XG, et al. Cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1. Oncogene 2019;38:1256-1268.
DOI
|
24 |
Jones LB, Bell CR, Bibb KE, Gu L, Coats MT, Matthews QL. Pathogens and their effect on exosome biogenesis and composition. Biomedicines 2018;6:E79.
DOI
|
25 |
Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 2010;285:17442-17452.
DOI
|
26 |
Wu XG, Zhou CF, Zhang YM, Yan RM, Wei WF, Chen XJ, et al. Cancer-derived exosomal miR-221- 3p promotes angiogenesis by targeting THBS2 in cervical squamous cell carcinoma. Angiogenesis 2019;22:397-410.
DOI
|
27 |
Liu YH, Liu JL, Wang Z, Zhu XH, Chen XB, Wang MQ. MiR-122-5p suppresses cell proliferation, migration and invasion by targeting SATB1 in nasopharyngeal carcinoma. Eur Rev Med Pharmacol Sci 2019;23:622-629.
|
28 |
Clancy C, Joyce MR, Kerin MJ. The use of circulating microRNAs as diagnostic biomarkers in colorectal cancer. Cancer Biomark 2015;15:103-113.
DOI
|